Trial Profile
A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms MUSIC
- Sponsors UCB
- 12 Nov 2017 Outcomes of a population pharmacokinetic model assessing exposure-response relationship of of certolizumab pegol using pooled data from nine clinical trials of certolizumab pegol induction and maintenance therapy in patients with Crohns disease, including C87005,C87031,C87032, C87037, C87042, C87043,C87047, C87048 and C87085, published in the Alimentary Pharmacology and Therapeutics Journal.
- 27 Apr 2012 Results have been published in Gut.
- 17 Oct 2010 Health-related quality-of-life data were presented in an absract at the 75th Annual Scientific Meeting of the American College of Gastroenterology.